# RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER

> **NCT02029729** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 11 (actual)

## Conditions studied

- Metastatic or Incurable Non-small Cell Lung Cancer
- Relapsed, Refractory Melanoma

## Interventions

- **DRUG:** omaveloxolone

## Key facts

- **NCT ID:** NCT02029729
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-31
- **Primary completion:** 2015-10-01
- **Final completion:** 2015-10-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02029729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02029729, "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02029729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*